1
|
Cutrona MB, Wu J, Yang K, Peng J, Chen T. Pancreatic cancer organoid-screening captures personalized sensitivity and chemoresistance suppression upon cytochrome P450 3A5-targeted inhibition. iScience 2024; 27:110289. [PMID: 39055940 PMCID: PMC11269815 DOI: 10.1016/j.isci.2024.110289] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/27/2023] [Revised: 04/12/2024] [Accepted: 06/13/2024] [Indexed: 07/28/2024] Open
Abstract
Cytochrome P450 3A5 (CYP3A5) has been proposed as a predictor of therapy response in subtypes of pancreatic ductal adenocarcinoma cancer (PDAC). To validate CYP3A5 as a therapeutic target, we developed a high-content image organoid-based screen to quantify the phenotypic responses to the selective inhibition of CYP3A5 enzymatic activity by clobetasol propionate (CBZ), using a cohort of PDAC-derived organoids (PDACOs). The chemoresistance of PDACOs to a panel of standard-of-care drugs, alone or in combination with CBZ, was investigated. PDACO pharmaco-profiling revealed CBZ to have anti-cancer activity that was dependent on the CYP3A5 level. In addition, CBZ restored chemo-vulnerability to cisplatin in a subset of PDACOs. A correlative proteomic analysis established that CBZ caused the suppression of multiple cancer pathways sustained by or associated with a mutant form of p53. Limiting the active pool of CYP3A5 enables targeted and personalized therapy to suppress pro-oncogenic mechanisms that fuel chemoresistance in some PDAC tumors.
Collapse
Affiliation(s)
- Meritxell B. Cutrona
- Department of Chemical Biology and Therapeutics, St. Jude Children’s Research Hospital, Memphis, TN 38105-3678, USA
| | - Jing Wu
- Department of Chemical Biology and Therapeutics, St. Jude Children’s Research Hospital, Memphis, TN 38105-3678, USA
| | - Ka Yang
- Department of Structural Biology, St. Jude Children’s Research Hospital, Memphis, TN 38105-3678, USA
| | - Junmin Peng
- Department of Structural Biology, St. Jude Children’s Research Hospital, Memphis, TN 38105-3678, USA
- Department of Developmental Neurobiology, St. Jude Children’s Research Hospital, Memphis, TN 38105-3678, USA
| | - Taosheng Chen
- Department of Chemical Biology and Therapeutics, St. Jude Children’s Research Hospital, Memphis, TN 38105-3678, USA
| |
Collapse
|
2
|
Nair AB, Kumar S, Dalal P, Nagpal C, Dalal S, Rao R, Sreeharsha N, Jacob S. Novel Dermal Delivery Cargos of Clobetasol Propionate: An Update. Pharmaceutics 2022; 14:pharmaceutics14020383. [PMID: 35214115 PMCID: PMC8877216 DOI: 10.3390/pharmaceutics14020383] [Citation(s) in RCA: 8] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/12/2022] [Revised: 02/06/2022] [Accepted: 02/08/2022] [Indexed: 02/06/2023] Open
Abstract
Dermal disorders such as psoriasis and eczema are associated with modifications in the chemical and molecular composition of the skin. Clobetasol propionate (CP), a superpotent topical glucocorticoid, is widely used for the therapeutic management of various skin conditions, owing to its strong anti-inflammatory, antipruritic, vasoconstrictive, and antiproliferative activities. Safety studies demonstrated that CP is safer for a shorter period, however, with prolonged application, it shows secondary side effects such as photosensitivity, Cushing-like syndrome, allergic contact dermatitis, osteonecrosis, hypopigmentation, steroid acne, and skin atrophy. Therefore, the US FDA (United States Food and Drug Administration) has restricted the usage of CP to not more than 15 days. Research scientists addressed its several formulations and drug delivery issues, such as low water solubility, less stability, photodegradation, and poor absorption, by incorporating them into novel nanobased delivery platforms. With the utilization of these technologies, these drawbacks of CP have been resolved to a large extent to reestablish this moiety. This article explores the physicochemical properties and mechanism of action of CP. Additionally, an attempt has been made to discover and highlight the possible features of the novel nanosystems, including nanoemulsions, nanosponges, solid lipid nanoparticles, nanostructured lipid carriers, and nanogels, reported for CP. The stability and safety concerns of CP, along with its commercial status, are also discussed.
Collapse
Affiliation(s)
- Anroop B. Nair
- Department of Pharmaceutical Sciences, College of Clinical Pharmacy, King Faisal University, Hofuf 31982, Al-Ahsa, Saudi Arabia;
- Correspondence: (A.B.N.); (R.R.); Tel.: +966-536219868 (A.B.N.); +91-9991048560 (R.R.)
| | - Sunil Kumar
- Department of Pharmaceutical Sciences, Guru Jambheshwar University of Science and Technology, Hisar 125001, India; (S.K.); (P.D.); (C.N.); (S.D.)
| | - Pooja Dalal
- Department of Pharmaceutical Sciences, Guru Jambheshwar University of Science and Technology, Hisar 125001, India; (S.K.); (P.D.); (C.N.); (S.D.)
| | - Chahat Nagpal
- Department of Pharmaceutical Sciences, Guru Jambheshwar University of Science and Technology, Hisar 125001, India; (S.K.); (P.D.); (C.N.); (S.D.)
| | - Sweta Dalal
- Department of Pharmaceutical Sciences, Guru Jambheshwar University of Science and Technology, Hisar 125001, India; (S.K.); (P.D.); (C.N.); (S.D.)
| | - Rekha Rao
- Department of Pharmaceutical Sciences, Guru Jambheshwar University of Science and Technology, Hisar 125001, India; (S.K.); (P.D.); (C.N.); (S.D.)
- Correspondence: (A.B.N.); (R.R.); Tel.: +966-536219868 (A.B.N.); +91-9991048560 (R.R.)
| | - Nagaraja Sreeharsha
- Department of Pharmaceutical Sciences, College of Clinical Pharmacy, King Faisal University, Hofuf 31982, Al-Ahsa, Saudi Arabia;
- Department of Pharmaceutics, Vidya Siri College of Pharmacy, Off Sarjapura Road, Bangalore 560035, India
| | - Shery Jacob
- Department of Pharmaceutical Sciences, College of Pharmacy, Gulf Medical University, Ajman 4184, United Arab Emirates;
| |
Collapse
|
3
|
Svendsen MT, Jeyabalan J, Andersen KE, Andersen F, Johannessen H. Worldwide utilization of topical remedies in treatment of psoriasis: a systematic review. J DERMATOL TREAT 2016; 28:374-383. [PMID: 27786594 DOI: 10.1080/09546634.2016.1254331] [Citation(s) in RCA: 22] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/08/2023]
Abstract
OBJECTIVE To review published literature describing the global use of topical antipsoriatics. MATERIALS AND METHODS Search for English-language articles in Embase, Pubmed, PsycINFO and Cochrane Library. RESULTS Fifty-four selected publications were found, describing psoriasis patients' use of topical antipsoriatics, using six different methods to collect data. The eight most frequently used topical treatments from the regions North/South America, North/Central/South Europe, Asia, Middle East and Australia were: corticosteroids used by 16-79%, complementary and alternative medicines used by 10-62%, phototherapies used by 0.4-75%, calcipotriol used by 4.2-73%, corticosteroid/calcipotriol combinations used by 3.3-71%, tar used by 0.8-66%, anthralin used by 15% and emollients used as monotherapy by 1-23%. Rates of patient-reported adherence to topical remedies ranged from 51% to 90% and rates of patient-reported satisfaction with topical as it pertains to symptom control ranged from 12% to 52%. CONCLUSION The identified use patterns are varying and reflect a lack of data from large parts of the world and noncomparable studies using heterogeneous study designs. However, this study emphasizes the importance of medical professionals involvement of the patient with respect to choosing prescribed topical treatment and the possibility of patients' use of alternative treatments. More drug utilization studies, both survey and register based, from different parts of the world are needed to provide more conclusive evidence about patients' use of topical antipsoriatics.
Collapse
Affiliation(s)
- Mathias Tiedemann Svendsen
- a Department of Dermatology and Allergy Centre , Odense University Hospital , Odense C , Denmark.,b Dermatological Investigations Scandinavia, University of Southern Denmark , Odense C , Denmark.,c Centre for Innovative Medical Technology , Institute of Clinical Research, University of Southern Denmark , Odense C , Denmark
| | - Janithika Jeyabalan
- a Department of Dermatology and Allergy Centre , Odense University Hospital , Odense C , Denmark
| | - Klaus Ejner Andersen
- a Department of Dermatology and Allergy Centre , Odense University Hospital , Odense C , Denmark.,b Dermatological Investigations Scandinavia, University of Southern Denmark , Odense C , Denmark.,c Centre for Innovative Medical Technology , Institute of Clinical Research, University of Southern Denmark , Odense C , Denmark
| | - Flemming Andersen
- a Department of Dermatology and Allergy Centre , Odense University Hospital , Odense C , Denmark.,b Dermatological Investigations Scandinavia, University of Southern Denmark , Odense C , Denmark
| | - Helle Johannessen
- d Research Unit of User Perspectives, Department of Public Health , University of Southern Denmark , Odense C , Denmark
| |
Collapse
|
4
|
Calcipotriol–captisol inclusion complex and corticosteroid in a novel fixed dose combination: evaluation on human epidermal keratinocyte cells. J INCL PHENOM MACRO 2015. [DOI: 10.1007/s10847-015-0572-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
5
|
Mrowietz U, Chouela EN, Mallbris L, Stefanidis D, Marino V, Pedersen R, Boggs RL. Pruritus and quality of life in moderate-to-severe plaque psoriasis: post hoc explorative analysis from the PRISTINE study. J Eur Acad Dermatol Venereol 2014; 29:1114-20. [PMID: 25376448 DOI: 10.1111/jdv.12761] [Citation(s) in RCA: 59] [Impact Index Per Article: 5.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/03/2014] [Accepted: 09/05/2014] [Indexed: 01/20/2023]
Abstract
BACKGROUND Pruritus is a clinically important symptom of psoriasis that has a major impact on quality of life (QoL). OBJECTIVE The objective of this study was to examine pruritus and QoL in patients with moderate-to-severe psoriasis treated with etanercept (ETN) in the PRISTINE clinical trial. METHODS Patients were randomized (1 : 1, double-blind) to ETN 50 mg QW or 50 mg BIW for 12 weeks, followed by 50 mg QW for 12 weeks. Pruritus was reported as 0 (no itching) to 5 (severe itching). Associations were examined between pruritus and Psoriasis Area and Severity Index, Dermatology Life Quality Index (DLQI), Hospital Anxiety and Depression Screening (HADS), Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue), Euro-Qol 5D (EQ-5D) and Medical Outcomes Study (MOS) Sleep Index II. RESULTS At baseline, patients (n = 270) had a mean pruritus level of 3.6. Itching (level ≥1) was reported by 96% of patients, 62% of whom had severe itching (level ≥4) and 26% had the highest level of itching. DLQI, HADS-Anxiety, HADS-Depression, FACIT-Fatigue, EQ-5D visual analog scale, and MOS Sleep Index II were significantly associated with itch. At week 12, mean pruritus improvement in the ETN BIW/QW group was greater than in the QW/QW group (2.4 vs. 1.6, P < 0.001), but not at week 24 (2.2 vs. 2.0, P = 0.180). Patients with the most severe itching at baseline (score of 5) had a mean score of 1.7 at week 24. Overall, patients with clinically meaningful pruritus improvement at week 24 reported greater improvement in QoL measures than other patients. CONCLUSION Most patients with moderate-to-severe psoriasis in this study (96%) reported pruritus. Pruritus improved significantly with ETN therapy and was strongly associated with improvements in QoL. These data support the clinical relevance of pruritus as an important symptom of patients with moderate/severe psoriasis.
Collapse
Affiliation(s)
- U Mrowietz
- Psoriasis Center at the Department of Dermatology, University Medical Center Schleswig-Holstein, Campus Kiel, Germany
| | - E N Chouela
- Hospital General de Agudos, Buenos Aires, Argentina
| | | | - D Stefanidis
- Pfizer Specialty Care, Medical Affairs Europe, Inflammation, Rome, Italy
| | - V Marino
- Pfizer Italia S.r.l., Rome, Italy
| | | | - R L Boggs
- Formerly of Pfizer Inc, Collegeville, PA, USA
| |
Collapse
|
6
|
Akasaka E, Mabuchi T, Manabe Y, Yahagi E, Yamada-Hiruma A, Yamaoka H, Kojima T, Kato M, Ikoma N, Ozawa A, Haruki Y. Long-term efficacy of psoriasis vulgaris treatments: Analysis of treatment with topical corticosteroid and/or vitamin D3analog, oral cyclosporin, etretinate and phototherapy over a 35-year period, 1975-2010. J Dermatol 2013; 40:238-43. [DOI: 10.1111/1346-8138.12069] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/06/2012] [Accepted: 11/19/2012] [Indexed: 12/01/2022]
Affiliation(s)
- Emiko Akasaka
- Department of Dermatology; Tokai University School of Medicine; Kanagawa; Japan
| | - Tomotaka Mabuchi
- Department of Dermatology; Tokai University School of Medicine; Kanagawa; Japan
| | - Yasuaki Manabe
- Department of Dermatology; Tokai University School of Medicine; Kanagawa; Japan
| | - Eiichiro Yahagi
- Department of Dermatology; Tokai University School of Medicine; Kanagawa; Japan
| | - Azusa Yamada-Hiruma
- Department of Dermatology; Tokai University School of Medicine; Kanagawa; Japan
| | - Hanako Yamaoka
- Department of Dermatology; Tokai University School of Medicine; Kanagawa; Japan
| | - Tomoko Kojima
- Department of Dermatology; Tokai University School of Medicine; Kanagawa; Japan
| | - Masayuki Kato
- Department of Dermatology; Tokai University School of Medicine; Kanagawa; Japan
| | - Norihiro Ikoma
- Department of Dermatology; Tokai University School of Medicine; Kanagawa; Japan
| | - Akira Ozawa
- Department of Dermatology; Tokai University School of Medicine; Kanagawa; Japan
| | - Yasuo Haruki
- Department of Basic Medical Science; Tokai University School of Medicine; Kanagawa; Japan
| |
Collapse
|
7
|
Albrecht L, Bourcier M, Ashkenas J, Papp K. Topical Psoriasis Therapy in the Age of Biologics: Evidence-Based Treatment Recommendations. J Cutan Med Surg 2011; 15:309-21. [DOI: 10.2310/7750.2011.10080] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/18/2022]
Abstract
Background: Although the range of therapeutic options has expanded dramatically in recent years, topical agents remain ubiquitous and indispensable tools for treating psoriasis at all levels of severity. The 2009 Canadian psoriasis guidelines considered evidence supporting various monotherapies and combination regimens. Objective: Here we review all approved topical agents, including corticosteroids, calcineurin inhibitors, vitamin D analogues, and retinoids, used in psoriasis and develop additional treatment recommendations, using the Scottish Intercollegiate Guidelines Network (SIGN) system to evaluate strength of evidence, as in the original guidelines. Conclusion: We propose that topical treatments have a place in the long-term management of patients with moderate to severe plaque psoriasis, including those receiving concomitant photo- or systemic therapy. Topical agents are effective and appropriate treatments for psoriasis as long as the physician is attentive to signs of local adverse events and seeks opportunities to reduce the dose or treatment frequency during chronic use.
Collapse
Affiliation(s)
- Lorne Albrecht
- From Guildford Dermatology, Surrey, BC; Durondel C.P. Inc., Moncton, NB; affiliated with the Universite de Sherbrooke, Sherbrooke, QC; and K. Papp Clinical Research and Probity Medical Research, Waterloo, ON
| | - Marc Bourcier
- From Guildford Dermatology, Surrey, BC; Durondel C.P. Inc., Moncton, NB; affiliated with the Universite de Sherbrooke, Sherbrooke, QC; and K. Papp Clinical Research and Probity Medical Research, Waterloo, ON
| | - John Ashkenas
- From Guildford Dermatology, Surrey, BC; Durondel C.P. Inc., Moncton, NB; affiliated with the Universite de Sherbrooke, Sherbrooke, QC; and K. Papp Clinical Research and Probity Medical Research, Waterloo, ON
| | - Kim Papp
- From Guildford Dermatology, Surrey, BC; Durondel C.P. Inc., Moncton, NB; affiliated with the Universite de Sherbrooke, Sherbrooke, QC; and K. Papp Clinical Research and Probity Medical Research, Waterloo, ON
| |
Collapse
|
8
|
Feldman SR, Yentzer BA. Topical clobetasol propionate in the treatment of psoriasis: a review of newer formulations. Am J Clin Dermatol 2009; 10:397-406. [PMID: 19824740 DOI: 10.2165/11311020-000000000-00000] [Citation(s) in RCA: 30] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/02/2022]
Abstract
Ultrapotent topical corticosteroids are the mainstay of psoriasis treatment, used either alone or in combination with a topical vitamin D analog. Traditionally used in an ointment vehicle for psoriasis, clobetasol propionate 0.05% is also available in spray, foam, lotion, and shampoo formulations, which may provide for improved convenience and acceptance in many patients with similar efficacy, safety, and tolerability as the traditional ointment and cream formulations. To compare newer formulations with traditional ointment and cream formulations, we performed a systematic review of the literature. Search terms included 'clobetasol propionate,' in combination with 'psoriasis,' 'vasoconstriction,' 'vasoconstrictor,' or 'absorption' for each of the four vehicles ('spray,' 'foam,' 'lotion,' and 'shampoo'). While there are very few direct comparison studies between clobetasol propionate in different vehicles, the efficacy rates (with success defined as clear or almost clear of psoriasis) for more recent formulations are high, with most patients achieving success after 2-4 weeks of treatment in well controlled clinical trials, with response rates that are similar to those with the traditional clobetasol propionate ointment. Small differences in vasoconstrictor potency or cutaneous absorption have been noted among the formulations, but the clinical significance of these observations is difficult to discern. Recent research has emphasized the importance of treatment adherence in the management of psoriasis. Adherence to treatment is likely to be a far more important determinant of success than are small differences in drug delivery, especially in actual clinical use as opposed to the well controlled environment of clinical trials. For patients who prefer a less messy vehicle, adherence and outcomes are likely to be better with the more recent formulations compared with the traditionally recommended ointment.
Collapse
Affiliation(s)
- Steven R Feldman
- Wake Forest University School of Medicine, Winston-Salem, North Carolina 27157-1071, USA.
| | | |
Collapse
|
9
|
Abstract
Psoriasis is a common, chronic, distressing skin disorder that frequently affects the scalp, skin, nails and joints. Despite treatment, many patients suffer from unremitting disease and decreased quality of life. Scalp-type psoriasis is particularly difficult to treat. Although topical corticosteroids are the mainstay of therapy for moderate-to-severe disease, patients frequently object to the messiness and unfavourable cosmetic appearance of topical treatments. In this context, foam vehicles, which have the advantage of minimal residue and increased ease of application, have emerged as novel alternatives to traditional creams, ointments and solutions. Clobetasol propionate foam 0.05% (OLUX, Connetics Corporation), a high potency topical steroid, has been shown to alleviate symptoms of several dermatological conditions, including scalp and body psoriasis, improve disease severity and increase quality of life. Dose should be limited to 50 g/week, given the risk of adrenal suppression. Because patient preference is an important determinant of medication efficacy in clinical practice, clobetasol foam is a useful new formulation in the treatment of psoriasis and other skin conditions.
Collapse
Affiliation(s)
- David C Reid
- Harvard Medical School, Clinical Unit for Research Trials in Skin, Massachusetts General Hospital, 275 Cambridge Street, Professional Office Building, 402, MA, USA.
| | | |
Collapse
|
10
|
|